Photodynamic therapy for age-related macular degeneration: A candid appraisal

American Journal of Ophthalmology

Volumn 137, Issue 3, 2004, Pages 483-485

  Sternberg Jr , Paul ^a   Lewis, Hilel ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FINANCIAL MANAGEMENT; FLUORESCENCE ANGIOGRAPHY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; LASER COAGULATION; MEDICAL ETHICS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; RETINA SURGERY; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 1542297330     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2003.11.023     Document Type: Article

References (2)

1. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin two-year results of 2 randomized clinical trials - TAP report no. 2. Arch Ophthalmol. 119:2001;198-207.
2. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol. 131:2001;541-560.